Author

Sheeraz Raja

Institution: Drugs for Neglected Diseases Initiative India

Observed institutions: Drugs for Neglected Diseases Initiative, Drugs for Neglected Diseases Initiative India

ORCID: 0009-0005-7591-4864

Observed ORCID: 0009-0005-7591-4864

OpenAlex ID: A5113258722

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

2024 · Shyam Sundar, Krishna Pandey, et al. · PLoS neglected tropical diseases · 21

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia

2024 · Semra Palić, Wan-Yu Chu, et al. · Journal of Antimicrobial Chemotherapy · 8

Bidirectional Interaction Between Liposomal Amphotericin B Pharmacokinetics and Parasite Dynamics in Patients With Post‐Kala‐Azar Dermal Leishmaniasis: Potential Implications for Optimal Dosing

2025 · Wan‐Yu Chu, Om Prakash Singh, et al. · Clinical Pharmacology & Therapeutics · 2

Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis

2026 · Wan-Yu Chu, Om Prakash Singh, et al. · International Journal of Antimicrobial Agents · 1

Works count: 4

Citation count: 32

H-index: 2

I10-index: 1